Form 4: Immunocore Holdings Director, William Pao, Reports Share Option Grant

Director William Pao reports the acquisition of share options in Immunocore Holdings plc.

Summary

• William Pao, a director of Immunocore Holdings plc, reported a transaction on February 25, 2025.
• Pao acquired 24,443 share options with an exercise price of $29.21.
• The options vest in equal monthly installments over three years, starting one month after February 25, 2025, contingent upon continuous service.
• The options expire on February 24, 2035.
• Following the transaction, Pao directly owns 24,443 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of share options is a standard practice and generally viewed as a positive incentive for the director, aligning their interests with shareholders.

Positives

• The grant of share options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Share option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard method of compensation for directors and executives.

Comparison to Industry Standards

• Share option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options to their directors and officers.
• The vesting schedule of three years is also standard practice, aligning with industry norms for long-term incentives.

Stakeholder Impact

• Shareholders may view the option grant as a positive incentive for the director.
• The director is incentivized to increase shareholder value through their continued service.

Key Dates